Evaluation of persistence and safety in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with ulcerative colitis
Latest Information Update: 28 Dec 2021
At a glance
- Drugs Ustekinumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms UC-EXTEND
- 20 Dec 2021 Status changed from not yet recruiting to recruiting.
- 06 Jul 2021 New trial record